Cargando…

Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon

An open-level, randomized and treatment-controlled clinical trial has shown that a therapeutic vaccine containing hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) (NASVAC) is endowed with antiviral and liver protecting capacity and is safer than pegylated interferon (Peg-IFN)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Mahtab, Mamun, Akbar, Sheikh Mohammad Fazle, Yoshida, Osamu, Aguilar, Julio Cesar, Guillen, Gerardo, Hiasa, Yoichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221800/ https://www.ncbi.nlm.nih.gov/pubmed/37243066 http://dx.doi.org/10.3390/vaccines11050962

Ejemplares similares

Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment
por: Al Mahtab, Mamun, et al.
Publicado: (2023)

Role of Pegylated Interferon in Patients with Chronic Liver Diseases in the Context of SARS-CoV-2 Infection
por: Akbar, Sheikh MF, et al.
Publicado: (2021)

Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2023)

Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022)

Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B
por: Aguilar, Julio Cesar, et al.
Publicado: (2022)

The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)
por: Al Mahtab, Mamun, et al.
Publicado: (2018)

Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022)

Immune therapies against chronic hepatitis B
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022)

HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis
por: Fleites, Yoel A, et al.
Publicado: (2021)

Implications of Birth-Dose Vaccination against Hepatitis B Virus in Southeast Asia
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac
por: Fernández, Guillermo, et al.
Publicado: (2018)

Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
por: Shiraishi, Kana, et al.
Publicado: (2023)

EDITORIAL
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2019)

The Journal in the Horizon of Asia and Europe
por: Fazle Akbar, Sheikh Mohammad, et al.
Publicado: (2018)

Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2023)

Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy
por: Melendez-Mena, Daniel, et al.
Publicado: (2021)

Epidemiology of Hepatitis E Virus in an Urban Community in Dhaka City
por: Rahman, Salimur, et al.
Publicado: (2014)

Patterns of Hepatocellular Carcinoma After Direct Antiviral Agents and Pegylated-Interferon Therapy
por: Fatima, Tehreem, et al.
Publicado: (2020)

Unprecedented rise of monkeypox in Europe and America: Are Asian countries ready for a new outbreak during the ongoing COVID-19 pandemic?
por: Khan, Sakirul, et al.
Publicado: (2022)

Characterization of Liver Monocytic Myeloid-Derived Suppressor Cells and Their Role in a Murine Model of Non-Alcoholic Fatty Liver Disease
por: Yao, Liying, et al.
Publicado: (2016)

Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2014)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
por: Chen, Zhi-wei, et al.
Publicado: (2017)

Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response
por: Etoh, Reiko, et al.
Publicado: (2011)

Recent downhill course of COVID-19 at Rohingya refugee camps in Bangladesh: Urgent action solicited
por: Khan, Sakirul, et al.
Publicado: (2021)

Dengue Infections during COVID-19 Period: Reflection of Reality or Elusive Data Due to Effect of Pandemic
por: Khan, Sakirul, et al.
Publicado: (2022)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha
por: da Silva, Andréa Marques Vieira, et al.
Publicado: (2021)

High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C
por: Komatsu, Haruki, et al.
Publicado: (2020)

The Effect of the Hepatitis B Vaccine Derived from Genotype C on Infants Born to Mothers Infected with Genotype D
por: Michitaka, Kojiro, et al.
Publicado: (2020)

Risk of congenital birth defects during COVID-19 pandemic: Draw attention to the physicians and policymakers
por: Khan, Md Sakirul Islam, et al.
Publicado: (2020)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Hepatitis C Viral Kinetics as a Determinant of Stopping Pegylated Interferon and Ribavirin in Genotype 1 Infection
por: Kim, Do Young
Publicado: (2014)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)

Factors influencing therapeutic response to pegylated interferon plus ribavirin in the different genotypes of chronic hepatitis C
por: Heidari, Mehdi, et al.
Publicado: (2014)

Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients
por: Abdel-Moneim, Adel, et al.
Publicado: (2018)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
por: Zheng, Caixia, et al.
Publicado: (2019)

Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh
por: Raihan, Ruksana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_574122378h0khuk3bln32omd4l